Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butamirate is a non-narcotic antitussive (cough suppressant) used primarily for the symptomatic treatment of dry (non-productive) cough. It acts centrally on the cough center in the brainstem to inhibit the cough reflex and also exhibits bronchodilatory effects by relaxing bronchial muscles. Butamirate is not chemically or pharmacologically related to opioid alkaloids and does not cause dependence or significant central nervous system depression. It may also have mild anti-inflammatory properties and reduces airway resistance, making it useful in both acute and chronic respiratory conditions associated with dry cough. The drug is available in various oral forms such as syrups, tablets, and drops[1][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butamirate.